Clinical Trials

994 enrolled 10 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03221426 2026-03-09

KEYNOTE-585

1,007 enrolled 25 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT05645107 2025-12-16

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Phase 3 Recruiting

386 enrolled

LymphoidOther hematologic neoplasm

Agammaglobulinemia, Bacterial Infections, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03740165 2025-10-22

KEYLYNK-001

1,367 enrolled 29 charts

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05933577 2025-09-24

V940-001

1,089 enrolled

Dermatologic

Melanoma

NCT03834493 2025-07-18

KEYNOTE-641

1,244 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03834506 2025-07-18

KEYNOTE-921

1,030 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT06910514 2025-04-09

Efficacy and Safety of a Solution for Endoscopic Mucosal Resection of Colonic Lesions

52 enrolled

Colonic Neoplasms

NCT02043678 2025-02-19

ERA 223

806 enrolled 32 charts

Prostatic Neoplasms

NCT03515837 2024-11-22

MK-3475-789

492 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT04210115 2024-11-15

KEYNOTE 975

703 enrolled

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT02578680 2024-09-20

MK-3475-189

616 enrolled 19 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04799249 2024-08-01

PRESERVE 2

194 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04907227 2024-07-12

KEYNOTE-921

Phase 3 Terminated

81 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03950674 2024-06-10

MK-3475-189

40 enrolled 20 charts

Other hematologic neoplasm

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04571645 2024-04-15

AML

Phase 3 Terminated

9 enrolled 9 charts

Leukemia, Myeloid, Acute

NCT03066778 2022-10-03

KEYNOTE-604

453 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT01956812 2021-08-16

PANCRIT®-1

Phase 3 Terminated

334 enrolled

Pancreatic Neoplasms

NCT02453334 2021-05-11

IRON CLAD

244 enrolled 33 charts

Tumor-Agnostic

Neoplasms

NCT01579188 2012-04-19

LucaVax

Phase 3 Unknown

600 enrolled

Inoperable Stage III Non-small Cell Lung Cancer

NCT00951574 2012-02-01

Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)